Paper657168
VP-16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung.
Eagan RT and 6 others. Cancer Treat Rep, 1978. Cited by 71 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. VP-16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung. Papers, record 657168. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/657168
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- VP-16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adenocarcinoma | Major topic |
| Carcinoma, Squamous Cell | Major topic |
| Etoposide | Major topic |
| Lung Neoplasms | Major topic |
| Podophyllotoxin | Major topic |
| Adult | |
| Aged | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Time Factors |
Source PubMed
Cited by15
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 71 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 7,083,461 | VP16-213 and cyclophosphamide in non oat cell bronchogenic carcinoma. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/7083461 | PubMed |
| 7,083,460 | Phase II trial of VP16-213 in non-small cell lung cancer (NSCLC). | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/7083460 | PubMed |
| 7,044,594 | VP16-213 (etoposide). A critical review of its activity. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/7044594 | PubMed |
| 7,044,593 | The podophyllotoxin derivatives VP16-213 and VM26. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/7044593 | PubMed |
| 7,031,350 | [Etoposide VP 16--213)--a podophyllotoxinderivative with high antitumor activity (author's transl)]. | Klin Wochenschr | 1981 | https://conductscience.org/library/papers/7031350 | PubMed |
| 6,683,999 | cis-platinum and etoposide combination chemotherapy of advanced non-oat cell bronchogenic carcinoma. | Cancer Chemother Pharmacol | 1983 | https://conductscience.org/library/papers/6683999 | PubMed |
| 3,280,154 | Single-agent chemotherapy for advanced adenocarcinoma of the lung. A review. | Cancer Chemother Pharmacol | 1988 | https://conductscience.org/library/papers/3280154 | PubMed |
| 3,280,152 | Combination chemotherapy for advanced adenocarcinoma of the lung. A review. | Cancer Chemother Pharmacol | 1988 | https://conductscience.org/library/papers/3280152 | PubMed |
| 3,028,662 | Experience with ifosfamide combinations (etoposide or DDP) in non-small cell lung cancer. | Cancer Chemother Pharmacol | 1986 | https://conductscience.org/library/papers/3028662 | PubMed |
| 2,414,458 | Update in cancer chemotherapy, Part III: Lung cancer, Part 1. | J Natl Med Assoc | 1985 | https://conductscience.org/library/papers/2414458 | PubMed |
| 2,265,460 | Carboplatin and etoposide in advanced lung cancer:--a phase I study. | Cancer Chemother Pharmacol | 1990 | https://conductscience.org/library/papers/2265460 | PubMed |
| 2,170,044 | Phase II study of carboplatin in untreated, inoperable non-small-cell lung cancer. | Cancer Chemother Pharmacol | 1990 | https://conductscience.org/library/papers/2170044 | PubMed |
| 1,655,301 | Phase II study of mitomycin C, etoposide and vindesine in metastatic stage IV non-small-cell lung cancer. | Cancer Chemother Pharmacol | 1991 | https://conductscience.org/library/papers/1655301 | PubMed |
| 1,645,622 | Etoposide in patients with previously untreated non-small-cell lung cancer: a phase I study. | Cancer Chemother Pharmacol | 1991 | https://conductscience.org/library/papers/1645622 | PubMed |
| 389,478 | Podophyllotoxin derivative VP 16-213. | Cancer Chemother Pharmacol | 1979 | https://conductscience.org/library/papers/389478 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/657168
GET https://conductscience.org/api/papers/v1/657168/authors